BREAKING Publication--Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for siRNA and RIBOTAC Therapy

petermcculoughmd.substack.com/p/breaking-publication-strategic-deactivation

Peter A. McCullough, MD, MPH

By Peter A. McCullough, MD, MPH

As the world is waking up to nearly two thirds with potential future disease and disability from the long-lasting mRNA coding for the dangerous Wuhan Spike protein, the search is on for ways to stop this molecular monster from doing more damage.

Hulscher et al have published a timely manuscript for the Bio-Pharmaceutical Complex looking for large markets needing new molecular therapeutics:

> "The stability of mRNA vaccines, their pervasive distribution, and the longevity of the encapsulated mRNA along with unlimited production of the damaging and potentially lethal Spike (S) protein call for strategies to mitigate potential adverse effects. Here, we explore the potential of small interfering RNA (siRNA) and ribonuclease targeting chimeras (RIBOTACs) as promising solutions to target, inactivate, and degrade residual and persistent vaccine mRNA, thereby potentially preventing uncontrolled Spike protein production and reducing toxicity. The targeted nature of siRNA and RIBOTACs allows for precise intervention, offering a path to prevent and mitigate adverse events of mRNA-based therapies. This review calls for further research into siRNA and RIBOTAC applications as antidotes and detoxication products for mRNA vaccine technology."

It may seem unfathomable for doctors to inject more RNA to deactivate Pfizer and Moderna synthetic mRNA that has accumulated in the body after multiple injections. However, siRNA used today in my practice (patisiran, inclisiran) appears to be safe and well-tolerated only notable for injection site reactions.

Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024). Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy. OSF Preprints. https://doi.org/10.31219/osf.io/qxbgu

Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy

Nicolas Hulscher, MPH, BSc[1]*, Peter A. McCullough, MD, MPH[1], Diane E. Marotta, PhD[2]



Figure 1: mRNA Construct Design for Therapeutic Applications. Five primary modifications include 5' capping efficiency and structure; UTR structure, length, and regulatory elements; modification of coding sequence; poly-A-tail properties; mRNA purity.

**Figure reprinted from Jackson et al [19]. The figure legend title has been adapted. Permission to use this figure has been granted in accordance with the open access Creative Common CC BY 4.0 license.*



Figure 2: Putative Biodistribution of mRNA after BNT162b2 and mRNA-1273 COVID-19 Vaccine Administration. COVID-19 vaccines inject lipid nanoparticles (LNPs) containing mRNA that encodes for the Spike protein. Proxy construct studies demonstrate that LNPs and mRNA are widely distributed and persist throughout the body.

**Created with Biorender.com.*



Figure 3: Methods to Target and Degrade Residual and Persistent COVID-19 Vaccine mRNA. A: siRNA targeted against COVID-19 vaccine mRNA enters the vaccinated cell via LNPs, where it incorporates into the RISC. The siRNA in RISC binds to the complementary sequence of the target vaccine mRNA and cleaves it, thus suppressing Spike protein production. **B:** RIBOTACs targeted against COVID-19 vaccine mRNA enter the vaccinated cell via LNPs, where they bind to both the target vaccine mRNA and endogenous RNase. This results in RNase-mediated vaccine mRNA degradation and the suppression of Spike protein production.

**Created with Biorender.com.*

Abbreviations: LNPs: Lipid Nanoparticles, mRNA: Messenger Ribonucleic Acid, RIBOTACs: Ribonuclease Targeting Chimeras, RISC: RNA-induced Silencing Complex, RNase: Ribonuclease, siRNA: Small Interfering Ribonucleic Acid.

Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024, May 30). Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy. https://doi.org/10.31219/osf.io/qxbgu

Please subscribe to *Courageous Discourse* as a paying or founder member so we can continue to bring you the truth.

Peter A. McCullough, MD, MPH

President, McCullough Foundation

www.mcculloughfnd.org

Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024, May 30). Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy. https://doi.org/10.31219/osf.io/qxbgu

Subscribe to Courageous Discourse™ with Dr. Peter McCullough & John Leake

.

Share

...